Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.5K

Association between the growth arrest-specific 6 (Gas6) gene polymorphism c.834 + 7G>A and preeclampsia

Ozlem Bingol Ozakpinar1, Sadık Sahin2, Nihan Verimli1

  • 1a Department of Biochemistry, Faculty of Pharmacy , Marmara University , Istanbul , Turkey .

The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
|April 28, 2015
PubMed

Insights

The Growth Arrest-Specific 6 (Gas6) gene polymorphism and lower plasma Gas6 levels are linked to preeclampsia (PE). The A allele of the GAS6 c.834 + 7G > A polymorphism appears to offer protection against PE development.

Area of Science:

  • Reproductive Medicine
  • Genetics
  • Biochemistry

Background:

  • Preeclampsia (PE) affects 2-8% of pregnancies, with unknown pathophysiology.
  • Growth Arrest-Specific 6 (Gas6) is implicated in atherothrombotic disease and angiogenesis.
  • Gas6's role in PE pathogenesis requires further investigation.

Purpose of the Study:

  • To examine the association between the GAS6 c.834 + 7G > A polymorphism, plasma Gas6 levels, and preeclampsia.
  • To determine if Gas6 influences PE risk.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) for plasma Gas6 quantification.
  • Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) for GAS6 genotyping.
  • Study included 82 preeclamptic and 68 normotensive pregnant women.

Main Results:

  • Preeclamptic women exhibited significantly lower plasma Gas6 levels than normotensive controls (p < 0.001).
  • The GG genotype was associated with a 3.5-fold increased risk of PE compared to the AA genotype (p < 0.01).
  • The A allele was less frequent in preeclamptic patients (OR = 2.118, p < 0.001).

Conclusions:

  • The GAS6 c.834 + 7G > A polymorphism plays a significant role in PE pathogenesis.
  • The A allele of the GAS6 polymorphism may confer a protective effect against preeclampsia.
Abstract

Keywords:
GAS6 polymorphisminflammationpreeclampsia

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis05:30

Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis

Published on: November 8, 2024

1.1K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
17.3K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
126
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
150
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69